Business Wire

Fluence Expands Footprint in Burgeoning Israeli Cannabis Industry, Supports Multiple Cultivators Through REMY Partnership

Share

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its implementations with two major cannabis cultivators in Israel, Springs Valley Cannabis LTD and UNIVO Pharmaceuticals (UNIVO), through Fluence’s ongoing partnership with REMY LTD (REMY), a leading, Israel-based horticultural lighting provider to the country’s growing agriculture industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005120/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence by OSRAM announced implementations with two major cannabis cultivators in Israel, Springs Valley Cannabis and UNIVO, through Fluence’s ongoing partnership with REMY, a leading horticultural lighting provider to the country’s growing agriculture industry. Photo courtesy of Fluence by OSRAM

Following the legalization of medical cannabis in 1993, Israel’s cannabis industry has flourished through in-depth research into efficient production and cultivation processes. With nearly 30 cultivators actively producing medical cannabis and dozens in planning stages, Israel is poised to meet and exceed demand for the estimated 100,000 medical cannabis users throughout the country. As legislation to legalize recreational cannabis use is evaluated, experts predict the industry will maintain its exponential growth trajectory.

“The rapid growth of the medical cannabis industry in Israel is a clear indicator of the recreational market’s potential,” said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. “To maintain the industry’s pace, cultivators must examine and invest in highly efficient production methods that yield consistent, high-quality cannabis products. Lighting plays one of the most crucial roles in that production process.”

Optimal lighting strategies for every phase of the cultivation value chain

Whether seed and variety breeding, cloning and growing plants, or the final cultivation of dense and full buds, each phase of the cannabis value chain requires optimized, curated lighting conditions. Fluence not only offers the industry’s leading LED lighting solutions, but provides evidence-based best practices to identify, implement and maintain the optimal lighting strategy at each phase of cannabis growth. Fluence’s research-backed cultivation methods supported by its team of horticulture specialists enable cannabis cultivators to achieve high-quality, consistent crops while conserving heating, ventilation and air conditioning costs.

REMY echoes Fluence’s cultivation philosophy and approach. Through their partnership, Fluence and REMY are serving Israel’s most innovative cultivators. Springs Valley Cannabis, located in Northern Israel, relies on Fluence’s LED technology in its large-scale, high-end indoor growing facility to ensure superior cannabis flowering within the company’s first cultivation environment.

“Lighting has a major effect on our high-end indoor farm's success,” said Yair Shaked, CEO at Springs Valley Cannabis. “We searched for a lighting partner that would support us and add value for the long run—that's why we chose to work with REMY and Fluence.”

UNIVO, a vertically integrated medical cannabis company covering all aspects of cultivation, manufacturing and distribution, leverages Fluence’s solutions in different stages of the growth cycle, including nursery, vegetative, flowering, mother stock, and research and development, where UNIVO clones and grows cannabis plants.

“Amit farm by UNIVO is one of the most sophisticated and technological farms in the Israeli cannabis industry, and after carefully reviewing the market, we decided to cooperate with Fluence to achieve the best premium cannabis flowers,” added Golan Bitton, CEO at UNIVO.

Continuous investment in new knowledge

“Amid Israel’s revered, dynamic high-tech industry, Fluence’s LED lighting technology is recognized as truly innovative. To maintain that position, we continuously invest in new knowledge and develop new techniques to best serve the world’s cultivators,” Bongartz added.

Fluence works closely with leading research institutions such as Wageningen University & Research to uncover new cultivation strategies and explore the influence of various light spectra on cannabis growth and development. Fluence’s collaborative research insights inform product innovations and provide growers with effective best practices to optimize plant growth.

“The job doesn’t stop when the light fixtures have been installed,” says Jörg Meyer-Brenken, Fluence’s lead account manager for cannabis in EMEA. “On the contrary, that’s when it starts and that’s where the Fluence and REMY teams add extraordinary value. REMY is a true, reliable partner. Their team combines deep lighting knowledge with years of experience in Israeli agriculture and horticulture, making REMY an ideal partner to help us reach a prominent position in this fast-growing market.”

“The end result for the cultivator is an agronomic lighting fixture, but the path to reach the optimal lighting strategy is driven by years of research and practical knowledge,” said Elad Toby, founder, CTO and chief business development officer for REMY. “There is huge opportunity in bringing Fluence’s groundbreaking knowledge to the Israeli medical cannabis market.”

For more information about Fluence, visit www.fluence.science.

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science.

About REMY

Established in 2008, REMY 108 LTD specializes in the planning, installation, supervision and quality assurance of large-scale lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its showroom and headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For EMEA,
Silvia Nagyova
+49 (89) 6213-3939
s.nagyova@osram.com

For North America,
Emma Chase
emma@redfancommunications.com
512-917-4319

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release

Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom